<div id="readability-page-1"><div>Dynavax Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick &amp; Foti, LLC (“KSF”) are investigating the proposed sale of Dynavax Technologies Corporation (NasdaqGS: DVAX) to Sanofi (NYSE: SNY). Under the terms of the proposed transaction, shareholders of Cidara will receive $221.50 in cash for each share of Cidara that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-cdtx/ to learn more. Please note that the transaction is structured as a tender offer, such that time may be of the essence. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com. CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNTEyMjk4MTk0MTNyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNTEyMjk4MTk0MTNyMQ"/> Kahn Swick &amp; Foti, LLC Lewis S. Kahn, Managing Partner lewis.kahn@ksfcounsel.com 855-768-1857 1100 Poydras St., Suite 960 New Orleans, LA 70163 View source version on businesswire.com: https://www.businesswire.com/news/home/20251229819413/en/</div></div>

德納維制藥

賽諾菲

Kahn Swick & Foti, LLC 正在調查賽諾菲（Sanofi，SNY）擬收購 Dynavax Technologies Corporation（DVAX）的提議。該律師事務所旨在評估每股 221.50 美元的現金報價是否充分反映了公司的價值，以及銷售過程是否合適。認為該報價低估了 Dynavax 的股東被鼓勵聯繫 KSF，進行關於他們權利的法律討論。該交易以要約收購的形式進行，強調了及時行動的必要性

德納維製藥投資者警報：Kahn Swick & Foti, LLC 正在調查擬議出售德納維製藥公司 - DVAX 的價格和流程是否合理